University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute, Pittsburgh, PA
Robert L. Ferris , Maura L. Gillison , Jonathan Harris , A. Dimitrios Colevas , Loren K. Mell , Christina Kong , Richard Jordan , Kevin Moore , Minh Tam Truong , Claudia Kirsch , David Anthony Clump , James Ohr , Kai He , Dukagjin Blakaj , John F. Deeken , Mitchell Machtay , Walter John Curran Jr., Quynh-Thu Le
Background: Nivolumab, which inhibits the programmed death-1 (PD-1) receptor, improved survival for patients (pts) with platinum-refractory recurrent/metastatic HNSCC compared with standard therapy. This trial evaluates the safety of adding nivo to 4 standard radiotherapy (RT) regimens for pts with newly diagnosed IR/HR HNSCC (Table). Safety data for cohort 3 (cetuximab) are reported. Efficacy data for cohorts 1, 2, and 3 will be reported at the presentation. Methods: Eligibility includes IR (p16+, oropharynx (OP) T1-2N2b-N3/T3-4N0-3, >10 pack-years (pys) or T4N0-N3, T1-3N3 ≤10 pys) and HR HNSCC (oral cavity, larynx, hypopharynx, or p16(-) OP, stage T1-2N2a-N3 or T3-4N0-3). 10 pts are enrolled to obtain 8 evaluable pts. Primary endpoint is dose-limiting toxicity (DLT), defined as nivo-related: ≥grade 3 adverse event (AE) unresolved to ≤grade 1 in ≤28 days; RT delay >2 wks; incomplete RT; or inability to receive ≥70% of cetuximab. DLT window was from first nivo dose (day -14) to 28 days post RT. >2 DLTs in 8 evaluable pts is unacceptable. Results: Of 10 enrolled pts for cohort 3: median age 61.5, 80% male, 70% Caucasian, 70% PS 0, 80% >10 pys, 60% p16(+) OP cancer, 60% T3-4 and 100% N2-3 disease. 1 pt was inevaluable for DLT due to withdrawal of consent and 1 pt has not yet completed the DLT observation period. 1 DLT (mucositis) was reported in 8 evaluable pts; 1 other grade 3 AE attributed to nivo was reported (lipase increase) but was not a DLT. 11 SAEs in 3 pts, but none nivo-related. 7/8 pts completed RT, 7/8 pts completed cetuximab; 5 pts completed 10 concurrent doses of nivo, 1 pt received 6 doses, 1 pt 7 doses, and 1 pt is ongoing after 8 doses. Conclusions: Nivo is safe and feasible to administer concomitant with a cetuximab-RT regimen for patients with newly diagnosed IR/HR HNSCC. Clinical trial information: NCT02764593
Cohort | Cis Eligible | Nivo C: concurrent A: adjuvant | Chemotherapy | RT IMRT 70 Gy/7 wk | N enrolled |
---|---|---|---|---|---|
1 | Y | C: 240 mgs q14d X10 A: 480 mgs q28d X7 | Weekly Cis (40 mg/m2) | Y | 10 |
2 | Y | C : 240-360 mg q21d X6 A : 480 mg q28d X7 | High dose Cis (100 mg/m2 q 21d) | Y | 10 |
3 | Y | C: 240 mgs q14d X10 A: 480 mgs q28d X7 | Cetuximab | Y | 10 |
4 | N | C: 240 mgs q14d X10 A: 480 mgs q28d X7 | -- | Y | 5 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Takako Yoshii
2020 ASCO Virtual Scientific Program
First Author: Jennifer Maria Johnson
First Author: Igor Tsaur
2022 ASCO Annual Meeting
First Author: Akira Yabuno